Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Judith Wellens, Matthew Edmans, Uri Obolski, Colleen GC McGregor, Peter Simmonds, Marc Turner, Lisa Jarvis, Donal Skelley, Susanna Dunachie, Eleanor Barnes, David W Eyre, Jean-Frederic Colombel, Serre-Yu Wong, Paul Klenerman, James O Lindsey, Jack Satsangi, Craig P Thompson
doi: https://doi.org/10.1101/2021.10.13.21264916

Article usage

Article usage: October 2021 to December 2024

AbstractFullPdf
Oct 20215209157
Nov 2021222244
Dec 2021245251
Jan 20226177
Feb 202248110
Mar 202258516
Apr 20225006
May 202234214
Jun 202211918
Jul 202242110
Aug 20223218
Sep 20229429
Oct 20224408
Nov 20222205
Dec 20221519
Jan 20236107
Feb 20232447
Mar 20232403
Apr 202324410
May 20231418
Jun 20231142
Jul 20231014
Aug 202323148
Sep 20231865
Oct 20231627
Nov 20232343
Dec 20231235
Jan 2024832
Feb 20241647
Mar 2024632
Apr 20241634
May 20241315
Jun 20241714
Jul 20241406
Aug 202422511
Sep 20242623
Oct 202416510
Nov 202425516
Dec 2024402
Back to top
Posted October 18, 2021.
Download PDF
Data/Code
Email
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Judith Wellens, Matthew Edmans, Uri Obolski, Colleen GC McGregor, Peter Simmonds, Marc Turner, Lisa Jarvis, Donal Skelley, Susanna Dunachie, Eleanor Barnes, David W Eyre, Jean-Frederic Colombel, Serre-Yu Wong, Paul Klenerman, James O Lindsey, Jack Satsangi, Craig P Thompson
medRxiv 2021.10.13.21264916; doi: https://doi.org/10.1101/2021.10.13.21264916
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area